{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:15:07Z","timestamp":1793031307853,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24-EY017045"],"award-info":[{"award-number":["R24-EY017045"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01-EY022097"],"award-info":[{"award-number":["R01-EY022097"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000369"],"award-info":[{"award-number":["81000369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81271036"],"award-info":[{"award-number":["81271036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jconrel.2014.06.043","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T08:17:38Z","timestamp":1404375458000},"page":"172-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":217,"special_numbering":"C","title":["Ocular delivery of macromolecules"],"prefix":"10.1016","volume":"190","author":[{"given":"Yoo Chun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianggen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.06.043_bb0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12257-012-0095-1","article-title":"Current status and perspectives of biopharmaceutical drugs","volume":"17","author":"Ryu","year":"2012","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nbt.2794","article-title":"What's fueling the biotech engine\u20142012 to 2013","volume":"32","author":"Aggarwal","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd3790","article-title":"Wet AMD market","volume":"11","author":"Syed","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.preteyeres.2010.04.001","article-title":"Protein delivery for retinal diseases: from basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","author":"Kaur","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2004.04.008","article-title":"Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization","volume":"79","author":"Castro","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0055","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","article-title":"The effect of bevacizumab on corneal neovascularization in rabbits","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10792-013-9732-8","article-title":"The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization","volume":"33","author":"Acar","year":"2013","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/IJG.0b013e318170a747","article-title":"Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients","volume":"18","author":"Duch","year":"2009","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2008.0088","article-title":"Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma","volume":"25","author":"Yuzbasioglu","year":"2009","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.oftal.2011.09.025","article-title":"Intracameral bevacizumab (Avastin(R)) in the management of neovascular glaucoma surgery","volume":"87","author":"Fernandez Jimenez-Ortiz","year":"2012","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0085","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0090","article-title":"A phase 3 safety and efficacy study of Fovista\u2122 (E10030) intravitreous administration in combination with either Avastin\u00ae or Eylea\u00ae compared to Avastin\u00ae or Eylea\u00ae","year":"2014","journal-title":"monotherapy, in, U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","article-title":"Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins","volume":"332","author":"Binz","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ajo.2012.09.032","article-title":"Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"155","author":"Campochiaro","year":"2013","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0105","article-title":"A study of arc1905 (anti-c5 aptamer) in subjects with dry age-related macular degeneration, in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0110","article-title":"Arc 1905 (anti-c5 aptamer) given either in combination therapy with Lucentis\u00ae 0.5mg\/eye in subjects with neovascular age-related macular degeneration, in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0115","article-title":"A study of safety, tolerability, and evidence of activity of fcfd4514s administered monthly or every other month to patients with geographic atrophy, in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0120","article-title":"Intravitreal adalimumab in patients with choroidal neovascularization secondary to age-related macular degeneration, in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0130","first-page":"1","article-title":"The weight and growth of the human eyeball","volume":"12","author":"Todd","year":"1940","journal-title":"Hum. Biol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0135","series-title":"The Weight and Growth of the Human Eyeball","author":"Todd","year":"1940"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0039-6257(79)90158-9","article-title":"The blood\u2013ocular barriers","volume":"23","author":"Cunha-Vaz","year":"1979","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-60761-938-3_5","article-title":"The blood\u2013retinal barrier: structure and functional significance","volume":"686","author":"Runkle","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2012.00296","article-title":"The privileged immunity of immune privileged organs: the case of the eye","volume":"3","author":"Benhar","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0155","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(00)00110-7","article-title":"Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach","volume":"44","author":"Doughty","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0160","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1023\/A:1013061926851","article-title":"Predicted permeability of the cornea to topical drugs","volume":"18","author":"Edwards","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0165","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0170","first-page":"4093","article-title":"Corneal epithelial tight junctions and their response to lipopolysaccharide challenge","volume":"41","author":"Yi","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0175","doi-asserted-by":"crossref","first-page":"G250","DOI":"10.1152\/ajpgi.2000.279.2.G250","article-title":"Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins","volume":"279","author":"Mitic","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0180","first-page":"826","article-title":"Lysosomal hydrolases in tears and the lacrimal gland: effect of acetylsalicylic acid on the release from the lacrimal gland","volume":"19","author":"van Haeringen","year":"1980","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/IJG.0b013e31814b990d","article-title":"Barriers to glaucoma drug delivery","volume":"17","author":"Ghate","year":"2008","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0190","first-page":"684","article-title":"Paracellular permeability of corneal and conjunctival epithelia","volume":"30","author":"Huang","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0195","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1167\/iovs.06-0670","article-title":"Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging","volume":"48","author":"Kim","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0200","doi-asserted-by":"crossref","first-page":"783163","DOI":"10.1155\/2012\/783163","article-title":"Lymphatics and lymphangiogenesis in the eye","volume":"2012","author":"Nakao","year":"2012","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0205","first-page":"282","article-title":"Permeability of blood\u2013ocular barriers of neonatal and adult cats to fluorescein-labeled dextrans of selected molecular sizes","volume":"21","author":"Bellhorn","year":"1981","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0210","first-page":"1893","article-title":"Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning","volume":"36","author":"Olsen","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0215","first-page":"12","article-title":"Fiber matrix model of sclera and corneal stroma for drug delivery to the eye","volume":"44","author":"Aur\u00e9lie Edwards","year":"1998","journal-title":"AIChE J."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0220","first-page":"3054","article-title":"The effect of intraocular pressure on human and rabbit scleral permeability","volume":"40","author":"Rudnick","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0014-4835(77)90136-1","article-title":"Diffusion across the sclera","volume":"25","author":"Maurice","year":"1977","journal-title":"Exp. Eye Res."},{"issue":"91","key":"10.1016\/j.jconrel.2014.06.043_bb0230","first-page":"e1-6","article-title":"Diffusion of macromolecules through sclera","author":"Miao","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0235","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.23387","article-title":"Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab","volume":"102","author":"Wen","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/jop.2007.0061","article-title":"Trans-scleral delivery of antiangiogenic proteins","volume":"24","author":"Demetriades","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0245","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0250","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/29.2.7252121","article-title":"Permeability of rat choriocapillaris to hemeproteins. Restriction of tracers by a fenestrated endothelium","volume":"29","author":"Pino","year":"1981","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0255","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/BF00218115","article-title":"Observations on the permeability of the choriocapillaris of the eye","volume":"231","author":"Essner","year":"1983","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0260","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000329794","article-title":"Diffusion of protein through the human cornea","volume":"48","author":"Charalel","year":"2012","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0265","first-page":"947","article-title":"The dynamics of IgG in the cornea","volume":"18","author":"Allansmith","year":"1979","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0270","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.2042-7158.2010.01153.x","article-title":"In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application","volume":"62","author":"Pescina","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0275","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity","volume":"46","author":"Pitkanen","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0280","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1167\/iovs.02-1027","article-title":"Human retinal molecular weight exclusion limit and estimate of species variation","volume":"44","author":"Jackson","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/138920007779815968","article-title":"Diffusion of macromolecule through retina after experimental branch retinal vein occlusion and estimate of intraretinal barrier","volume":"8","author":"Tao","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0290","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0295","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0300","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.2337\/diabetes.51.10.3107","article-title":"Pericytes and the pathogenesis of diabetic retinopathy","volume":"51","author":"Hammes","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.exer.2007.10.013","article-title":"Pericytes and ocular diseases","volume":"86","author":"Motiejunaite","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J. Angiogenes. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0315","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The retinal pigment epithelium in visual function","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0320","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.preteyeres.2007.02.002","article-title":"Transplantation of the RPE in AMD","volume":"26","author":"Binder","year":"2007","journal-title":"Prog. Retin. Eye Res."},{"issue":"Suppl.","key":"10.1016\/j.jconrel.2014.06.043_bb0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-4835(77)80009-2","article-title":"The structural basis of the blood\u2013ocular barriers","volume":"25","author":"Raviola","year":"1977","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0330","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/17425247.5.5.567","article-title":"Ocular novel drug delivery: impacts of membranes and barriers","volume":"5","author":"Barar","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00438-6","article-title":"Acetazolamide: future perspective in topical glaucoma therapeutics","volume":"248","author":"Kaur","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0340","first-page":"27","article-title":"Treatment of postoperative pain after ophthalmic surgery","author":"Coppens","year":"2002","journal-title":"Bull. Soc. Belge Ophtalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0345","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/bjo.2004.050054","article-title":"Penetration of moxifloxacin into the human aqueous humour after oral administration","volume":"89","author":"Kampougeris","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajo.2009.02.010","article-title":"Vitreous penetration of orally administered famciclovir","volume":"148","author":"Chong","year":"2009","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0355","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1167\/iovs.08-2370","article-title":"Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye","volume":"50","author":"Furrer","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0360","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/02713689508999927","article-title":"Ocular distribution of the chimeric protein IL2-PE40","volume":"14","author":"BenEzra","year":"1995","journal-title":"Curr. Eye Res."},{"issue":"2006","key":"10.1016\/j.jconrel.2014.06.043_bb0365","first-page":"e2001","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study","volume":"113","author":"Moshfeghi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0370","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1442-9071.2008.01911.x","article-title":"Penetration of 1% voriconazole eye drops into human vitreous humour: a prospective, open-label study","volume":"37","author":"Lau","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0375","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1167\/iovs.08-2372","article-title":"Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer","volume":"50","author":"Ottiger","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0380","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer. Adher."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0385","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0390","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0395","series-title":"Advances in Ocular Drug Delivery","first-page":"33","article-title":"Transscleral drug delivery to the posterior segment of the eye: particulate and colloidal formulations and biopharmaceutical considerations","author":"Srirangam","year":"2012"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0400","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10439-006-9238-x","article-title":"Protein transport to choroid and retina following periocular injection: theoretical and experimental study","volume":"35","author":"Mac Gabhann","year":"2007","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0405","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.11.016","article-title":"Charged nanoparticles delivery to the eye using hydrogel iontophoresis","volume":"126","author":"Eljarrat-Binstock","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0410","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s11095-008-9684-2","article-title":"Can ultrasound solve the transport barrier of the neural retina?","volume":"25","author":"Peeters","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0415","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/aic.690440123","article-title":"Fiber matrix model of sclera and corneal stroma for drug delivery to the eye","volume":"44","author":"Edwards","year":"1998","journal-title":"AIChE J."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0420","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","article-title":"Treatments for corneal neovascularization: a review","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0425","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","article-title":"Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique","volume":"30","author":"Hashemian","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0430","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0435","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/10807680152729257","article-title":"Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection","volume":"17","author":"Lee","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0440","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4065\/72.2.149","article-title":"Prophylactic antibiotics in cataract operations","volume":"72","author":"Liesegang","year":"1997","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0445","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archopht.1995.01100070025016","article-title":"Successful prevention of visual loss with emergency management following inadvertent intracameral injection of gentamicin","volume":"113","author":"Daily","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0450","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/ICO.0b013e31806c791e","article-title":"Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0455","first-page":"2326","article-title":"Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0460","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IJG.0b013e3181996ed2","article-title":"In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation","volume":"18","author":"Shin","year":"2009","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0465","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/ICO.0b013e318180e572","article-title":"Effect of intracameral bevacizumab injection on corneal endothelium in rabbits","volume":"27","author":"Park","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1167\/iovs.09-3947","article-title":"The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice","volume":"51","author":"Sappington","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0475","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1167\/iovs.02-0375","article-title":"Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate","volume":"44","author":"Okabe","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0480","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0485","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral drug delivery to the eye using hollow microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0490","first-page":"1181","article-title":"Diffusion of high molecular weight compounds through sclera","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0495","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0500","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0505","first-page":"1186","article-title":"Transscleral delivery of bioactive protein to the choroid and retina","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0510","series-title":"Vitravene (Fomivirsen Sodium Intravitreal Injectable) Injection","year":"1998"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0515","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0520","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ophtha.2005.10.061","article-title":"Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"113","author":"Benz","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0525","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.drudis.2010.02.004","article-title":"Delivery of anti-angiogenic molecular therapies for retinal disease","volume":"15","author":"Anderson","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0530","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration","volume":"22","author":"Eyetech Study","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0535","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age- related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0540","first-page":"3098","article-title":"Longitudinal changes in self-reported visual functioning in AMD patients in a randomized controlled Phase I\/II trial of Lucentis(TM) (ranizumab; rHuFAB v2)","volume":"45","author":"Chang","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0545","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"View, V.S. Groups, Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0550","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0555","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0560","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0565","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jconrel.2003.08.004","article-title":"Extracellular and intracellular barriers in non-viral gene delivery","volume":"93","author":"Ruponen","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0570","series-title":"Drug Product Development for the Back of the Eye","first-page":"173","article-title":"Suprachoroidal and intrascleral drug delivery","author":"Olsen","year":"2011"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0575","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0580","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2147\/OPTH.S46317","article-title":"Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)","volume":"7","author":"Otsuji","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0585","first-page":"864","article-title":"Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions","volume":"92","author":"Nigam","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0590","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/bjo.2006.113902","article-title":"Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions","volume":"91","author":"Lux","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0595","series-title":"Pharmacology of the Eye","author":"Chader","year":"1984"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0600","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0605","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0610","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0615","first-page":"1533","article-title":"Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye","volume":"43","author":"Einmahl","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0620","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0625","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0630","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0014-4835(71)90094-7","article-title":"Flow conductivity of retina and its role in retinal adhesion","volume":"12","author":"Fatt","year":"1971","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0635","first-page":"233","article-title":"Hydrostatic pressure of the suprachoroidal space","volume":"30","author":"Emi","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0640","article-title":"Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye","author":"Kim","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0645","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/jop.2013.0063","article-title":"Effect of choroidal perfusion on ocular tissue distribution after intravitreal or suprachoroidal injection in an arterially perfused ex vivo pig eye model","volume":"29","author":"Abarca","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0650","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0655","first-page":"155","article-title":"Vasodynamic and angiogenic effects of eicosanoids in the eye","volume":"312","author":"Stjernschantz","year":"1989","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0660","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/02713688609015120","article-title":"Effects of B-HT 920 in the eye and on regional blood flows in anaesthetized and conscious rabbits","volume":"5","author":"Thorig","year":"1986","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0665","series-title":"Advances in Organ Biology","author":"Fischbarg","year":"1996"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0670","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1350-9462(01)00002-7","article-title":"Confronting complexity: the interlink of phototransduction and retinoid metabolism in the vertebrate retina","volume":"20","author":"McBee","year":"2001","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0675","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0006-291X(82)80091-0","article-title":"Retinol-binding proteins in bovine interphotoreceptor matrix","volume":"108","author":"Adler","year":"1982","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0680","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","article-title":"Nanomedicines for back of the eye drug delivery, gene delivery, and imaging","volume":"36","author":"Kompella","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0685","first-page":"2211","article-title":"Technical brief: subretinal injection and electroporation into adult mouse eyes","volume":"14","author":"Johnson","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0690","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/108729001317022250","article-title":"Uptake dynamics and retinal tolerance of phosphorothioate oligonucleotide and its direct delivery into the site of choroidal neovascularization through subretinal administration in the rat","volume":"11","author":"Shen","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0695","first-page":"131","article-title":"Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina","volume":"7","author":"Timmers","year":"2001","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0700","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jgm.401","article-title":"Long-term evaluation of retinal function in Prph2Rd2\/Rd2 mice following AAV-mediated gene replacement therapy","volume":"5","author":"Schlichtenbrede","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0705","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0710","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000050849","article-title":"Biodegradable polymers for ocular drug delivery","volume":"215","author":"Kimura","year":"2001","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0715","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0720","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1167\/iovs.03-0600","article-title":"Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model","volume":"44","author":"Saishin","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0725","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.addr.2005.09.006","article-title":"Micro- and nanoparticulates","volume":"57","author":"Moshfeghi","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0730","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jpcs.2007.10.043","article-title":"Mucoadhesive microparticles engineered for ophthalmic drug delivery","volume":"69","author":"Bin Choy","year":"2008","journal-title":"J. Phys. Chem. Solids"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0735","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0740","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11095-009-0042-9","article-title":"New techniques for drug delivery to the posterior eye segment","volume":"27","author":"Eljarrat-Binstock","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0745","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety evaluation of ocular drug delivery formulations: techniques and practical considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0750","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/138920007779815977","article-title":"Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs","volume":"8","author":"Bu","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0755","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1389450053765914","article-title":"Colloidal carriers for ophthalmic drug delivery","volume":"6","author":"Mainardes","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0760","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/02713683.2011.652286","article-title":"Advances in ocular drug delivery","volume":"37","author":"Rawas-Qalaji","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0765","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/ICU.0b013e3281108000","article-title":"Drug delivery methods for posterior segment disease","volume":"18","author":"Hsu","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0770","first-page":"150","article-title":"Effect of circulation on the disposition and ocular tissue distribution of 20nm nanoparticles after periocular administration","volume":"14","author":"Amrite","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0775","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.exer.2006.04.014","article-title":"A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres","volume":"83","author":"Li","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0780","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1167\/iovs.01-1156","article-title":"Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres","volume":"44","author":"Carrasquillo","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0785","series-title":"Preparation and Characterization of Pegaptanib Sustained Release Microsphere Formulations for Intraocular Application","first-page":"B521","author":"Cook","year":"2006"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0790","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jconrel.2006.02.010","article-title":"Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery","volume":"112","author":"Gomes dos Santos","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0795","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1039\/b706939a","article-title":"Novel approaches in microparticulate PLGA delivery systems encapsulating proteins","volume":"17","author":"Taluja","year":"2007","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0800","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","article-title":"Intraocular sustained drug delivery using implantable polymeric devices","volume":"57","author":"Yasukawa","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0805","doi-asserted-by":"crossref","first-page":"895013","DOI":"10.1155\/2013\/895013","article-title":"Critical assessment of implantable drug delivery devices in glaucoma management","volume":"2013","author":"Manickavasagam","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0810","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00061-3","article-title":"Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy","volume":"55","author":"Zhou","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0815","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.2011.617741","article-title":"Road to remission: a comprehensive review of therapy in uveitis","volume":"20","author":"Siddique","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0820","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","article-title":"Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine\u2013Gass syndrome","volume":"147","author":"Williams","year":"2009","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0825","first-page":"126463","article-title":"Intravitreal devices for the treatment of vitreous inflammation","volume":"2012","author":"Christoforidis","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0830","article-title":"Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD), in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0835","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/1080768041223611","article-title":"Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period","volume":"20","author":"Driot","year":"2004","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0840","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.actbio.2013.12.014","article-title":"Biomaterials for orbital implants and ocular prostheses: overview and future prospects","volume":"10","author":"Baino","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0845","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0142-9612(00)00237-4","article-title":"Ocular biomaterials and implants","volume":"22","author":"Lloyd","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0850","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","article-title":"Intraocular implants for extended drug delivery: therapeutic applications","volume":"58","author":"Bourges","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0855","first-page":"66","article-title":"Cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"14","author":"Kedhar","year":"2007","journal-title":"Herpes"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0860","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0865","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterioruveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0870","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/IAE.0b013e31817d8bf2","article-title":"Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis","volume":"28","author":"Taban","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0875","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3- year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0880","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0885328211406563","article-title":"Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: preparation, characterization, and in vivo evaluation","volume":"27","author":"Chen","year":"2012","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0885","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3109\/03639041003801893","article-title":"Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide","volume":"36","author":"Qian","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0890","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jop.2009.0074","article-title":"Novel nanoparticulate gel formulations of steroids for the treatment of macular edema","volume":"26","author":"Boddu","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0895","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jbm.b.31498","article-title":"Toxicity evaluation of biodegradable and thermosensitive PEG-PCL-PEG hydrogel as a potential in situ sustained ophthalmic drug delivery system","volume":"92","author":"Yin","year":"2010","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0900","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/17425247.2012.690733","article-title":"Ocular drug delivery system: a reference to natural polymers","volume":"9","author":"Pahuja","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0905","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","article-title":"Recent advances in ocular drug delivery","volume":"39","author":"Achouri","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0910","doi-asserted-by":"crossref","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0915","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0920","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14712598.6.7.717","article-title":"Application of encapsulated cell technology for retinal degenerative diseases","volume":"6","author":"Tao","year":"2006","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0925","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trsl.2012.12.007","article-title":"Gene therapy for retinal disease","volume":"161","author":"McClements","year":"2013","journal-title":"Transl. Res."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0930","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/hum.2010.041","article-title":"Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease","volume":"21","author":"Roy","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0935","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","article-title":"Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants","volume":"103","author":"Sieving","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.06.043_bb0940","article-title":"A study of an encapsulated cell technology (ECT) implant for patients with atrophic macular degeneration, in","year":"2014","journal-title":"U.S. National Institutes of Health"},{"key":"10.1016\/j.jconrel.2014.06.043_bb0945","article-title":"Retinal imaging of subjects implanted with ciliary neurotrophic factor (cntf)-releasing encapsulated cell implant for early-stage retinitis pigmentosa, in","year":"2014","journal-title":"U.S. National Institutes of Health"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914004520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914004520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T19:16:53Z","timestamp":1598037413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914004520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":189,"alternative-id":["S0168365914004520"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.06.043","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular delivery of macromolecules","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}